Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.
Advertisement
Set Alert for Articles By Francesca Bruce

Latest From Francesca Bruce

Canada Attempts Biosimilar Balancing Act

Plans to make Canada’s biologics market more competitive for biosimilars are advancing as payers are planning consultations on how price negotiations for biosimilars and biologics will proceed.

Biosimilars Policy

Pfizer To Compromise On NICE Price For Ibrance?

NICE, the HTA for England and Wales, is poised to say no to Pfizer’s Ibrance (palbociclib), because the cost of the drug is too big in relation to its benefits. The company will likely have to come back with a patient access scheme to secure reimbursement.

Commercial Market Access

Canada First To OK Sanofi/Regeneron’s Sarilumab, But Struggle To Differentiate Looms

Sanofi/Regeneron’s Kevzara (sarilumab) has won its first worldwide approval for treating moderately to severely active rheumatoid arthritis from Health Canada. But as more regulators follow, the companies will face a battle to differentiate the drug from chief rival, Roche/Chugai’s Actemra (tocilizumab).

Approvals Market Access

Big Changes Are Afoot In Canada’s Private Medicines Market

Product Listing Agreements are on the rise in Canada’s private medicines market, which seems set to undergo some big changes. Drug companies may have to consider adapting their economic arguments and being more transparent.

Canada Market Access

Colombia’s Glivec Pricing Means “Worst Of Scenarios” For Pharma Industry

AFIDRO, the association representing Colombia’s research-based pharmaceutical industry, is taking the government to court over new pricing regulations that follow the controversial declaration of public interest for Novartis’ Glivec (imatinib).

Colombia Intellectual Property

Novartis Takes On Colombia Over Glivec Pricing

Novartis is taking Colombian authorities to court over moves to cut the price of its anticancer Glivec (imatinib) and warns that the intellectual property rights of other products are under threat. Companies selling hepatitis C drugs should pay attention as their products could be next to face similar measures.

Companies Intellectual Property
See All
Advertisement
UsernamePublicRestriction

Register